Cancer Is Big Business.

A Polish native named Stanislaw Burzynski attended Lublin Medical University where he graduated first in his class at age 24 and received his PhD in biochemistry the following year. While undergoing his research to acquire his PhD, Dr. Burzynski made a profound discovery. He found a strain of peptides in human blood and urine that had never before been recorded in biomedical research.

As his curiosity in these peptides evolved he made another profound observation, people who were inflicted with cancer seemed to lack these newly discovered peptides in both their blood and urine while those who were healthy and free of cancer appeared to have an abundance of these peptides.

Dr. Burzynski theorised that if he could somehow provide a way to chemically extract these peptides from the blood and urine of healthy donors and administer these peptides to those with cancer perhaps it could be useful in treating the disease. The treatment became known as antineoplaston therapy and this is the story of Dr. Burzynski’s near 50-year journey to obtain FDA-approved clinical trials of Antineoplastons. Defying the face of skepticism, legal attacks from state and federal agencies.